Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives
- PMID: 832019
- PMCID: PMC1604081
- DOI: 10.1136/bmj.1.6053.78
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives
Abstract
The rate of reversal of hypercalcaemia or hypercalciuria induced by calciferol, dihydrotachysterol, 1-alpha-hydroxycholecalciferol (1-alpha-OHD3), or 1-alpha, 25-dihydroxycholecalciferol (1-alpha, 25-(OH)2D3) was measured in three normal subjects, two patients with osteoporosis, and 14 patients with disorders resistant to vitamin D. The half time for reversal after stopping 1-alpha, 25 (OH)2D3 was less than that after stopping 1-alpha-OHD3, calciferol, or dihydrotachysterol. The differences observed were independent of the dose given or length of treatment. When 1-alpha-OHD3 or 1-alpha-25-(OH)2D3 was stopped patients with vitamin D resistant states (hypoparathyroidism, renal tubular hypophosphataemia, or chronic renal failure) showed less rapid reversal of hypercalcaemia and hypercalciuria than did normal subjects. These studies show one potential advantage of 1-alpha-25-(OH)2D3 over vitamin D, and possibly over 1-alpha-OHD3, in the management of vitamin D resistant states.
Similar articles
-
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.Lancet. 1978 Sep 30;2(8092 Pt 1):700-3. doi: 10.1016/s0140-6736(78)92702-2. Lancet. 1978. PMID: 80633 Clinical Trial.
-
Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).Endocrinol Jpn. 1985 Apr;32(2):305-15. doi: 10.1507/endocrj1954.32.305. Endocrinol Jpn. 1985. PMID: 2995014
-
Inhibition by calcitonin of hypercalcaemia induced by 1,25-dihydroxycholecalciferol.J Endocrinol. 1980 Apr;85(1):63-7. doi: 10.1677/joe.0.0850063. J Endocrinol. 1980. PMID: 6893056
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Dihydrotachysterol therapy for hypoparathyroidism: consequences of inadequate monitoring. Five cases and a review.Exp Clin Endocrinol Diabetes. 2005 Jul;113(7):376-80. doi: 10.1055/s-2005-865724. Exp Clin Endocrinol Diabetes. 2005. PMID: 16025398 Review.
Cited by
-
Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3557-65. doi: 10.1210/clinem/dgaa490. J Clin Endocrinol Metab. 2020. PMID: 32738041 Free PMC article.
-
Osteomalacia and chronic renal failure.J Clin Pathol. 1981 Nov;34(11):1295-307. doi: 10.1136/jcp.34.11.1295. J Clin Pathol. 1981. PMID: 7033299 Free PMC article. Review. No abstract available.
-
Treatment of osteoporosis with vitamin D.Osteoporos Int. 1997;7 Suppl 3:S140-6. doi: 10.1007/BF03194360. Osteoporos Int. 1997. PMID: 9536320 No abstract available.
-
Evidence that calcitonin stimulates 1,25-dihydroxyvitamin D production and intestinal absorption of calcium in vivo.J Clin Invest. 1986 Aug;78(2):456-61. doi: 10.1172/JCI112597. J Clin Invest. 1986. PMID: 3755446 Free PMC article.
-
Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.J Clin Endocrinol Metab. 2012 Feb;97(2):391-9. doi: 10.1210/jc.2011-1908. Epub 2011 Nov 16. J Clin Endocrinol Metab. 2012. PMID: 22090268 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources